A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme

Health Technology Assessment

Volumn 8, Issue 31, 2004, Pages

  Claxton, K ^a   Ginnelly, L ^a   Sculpher, M ^a   Philips, Z ^a   Palmer, S ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; EVIDENCE BASED MEDICINE; EXPERIMENTAL DESIGN; FEASIBILITY STUDY; FEEDBACK SYSTEM; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL INFORMATION; MEDICAL INFORMATION SYSTEM; MEDICAL LITERATURE; MEDICAL RESEARCH; NATIONAL HEALTH SERVICE; PILOT STUDY; QUESTIONNAIRE; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SYSTEM ANALYSIS; TASK PERFORMANCE;

EID: 4444284468     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8310     Document Type: Review

References (100)

1. Gross CP, Anderson GE, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. New Engl J Med 1999;340:1881-7.
2. Michaud CM, Murray CJ, Bloom BR. Burden of disease - implications for future research. JAMA 2001;285.
3. Townsend J, Buxton M. Cost-effectiveness scenario analysis for a proposed trial of hormone replacement therapy. Health Policy 1997;39:181-94.
4. Davies L, Drummond MF, Papanikolaou P. Prioritizing investments in health technology assessment. Int J Technol Assess Health Care 2000; 16:73-91.
5. Buxton M, Hanney S. Assessing payback from Department of Health Research and Development. Second report. HERG Research Report 24. Uxbridge: Brunel University; 1997.
6. Phelps CE, Parente ST. Priority setting in medical technology and medical practice assessment. Med Care 1990;28.
7. Raiffa H, Schlaifer R. Probability and statistics for business decisions. New York: McGraw-Hill, 1959.
8. Pratt J, Raiffa H, Schlaifer R. Introduction to statistical decision theory. Cambridge, MA: MIT Press; 1995.
9. Thompson KM, Evans JS. The value of improved national exposure information for perchloroethylene (perc): a case study for dry cleaners. Risk Anal 1997; 17:253-71.
10. Howard RA. Information value theory. IEEE Transactions on Systems Science and Cybernetics 1966;SSC2:22-6.
11. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-89.
12. Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18:341-64.
13. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996;5:513-24.
14. Claxton K, Walker S, Lacey L. Selecting treatments: a decision theoretic approach. J R Stat Soc 2000;163:211-25.
15. Claxton K, Thompson K. A dynamic programming approach to efficient clinical trial design. J Health Econ 2001;20:432-48.
16. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997;2:26-30.
17. Claxton K, Neuman PJ, Araki SS, Weinstein MC. The value of information: an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 2001;17:38-55.
18. Claxton K, Neumann P, Araki S, Weinstein MC. The efficient design of clinical trials: an application to the evaluation of treatment strategies for Alzheimer's disease. J Health Econ forthcoming.
19. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence. Lancet 2002; 360:711-15.
20. Fenwick E, Claxton K, Sculpher M. A Bayesian analysis of pre-operative optimisation of oxygen delivery [Abstract]. Med Decis Making 2000;20:481.
21. Fenwick E, Claxton K, Sculpher M, Briggs A. Improving the efficiency and relevance of health technology assessment: the role of decision analytic modelling. Centre for Health Economics Discussion Paper No. 179. York: Centre for Health Economics; 2000.
22. Palmer S, Fenwick E, Claxton K, Sculpher M. Applications of value of information using Bayesian numerical methods [Abstract]. Med Decis Making 2001;21:531.
23. Claxton K. Efficient fourth hurdle regulation: an application of value of information analysis to a sample of health technologies [Abstract]. Med Decis Making 2001;21:531.
24. Fleurence RL, Torgerson DJ. Setting priorities for research. Health Policy 2004. In press.
25. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effective models; a suggested framework and example of application. Pharmacoeconomics 2000;17:461-77.
26. Hammitt JK, Cave JAK. Research planning for food safety: a value of information approach. Santa Monica, CA: RAND Publication Series; 1991.
27. Hunink M, Glasziou P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein MC. Decision making in health and medicine. Cambridge: Cambridge University Press; 2001.
28. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17:479-500.
29. Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making 1986;6:85-92.
30. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985; 5:157-77.
31. Phelps C, Mushlin AI. On the near equivalence of cost-effectiveness analysis. Int J Technol Assess Health Care 1991;17:12-21.
32. Stinnett A, Mullahy J. Net health benefits: a new framework for the analvsis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18:S68-80.
33. Ades AE. Markov chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence, and the accurate assessment of uncertainty. Med Decis Making 2002;22:359-71.
34. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998;18:95-109.
35. The National Asthma Campaign Asthma Audit. Out in the open: a true picture of asthma in the UK today. Asthma Journal 2001;6 Special Suppl.
36. Hondras MA, Linde K, Jones AR Manual therapy for asthma (Cochrane Review). In The Cochrane Library (Issue 2). Oxford: Update Software; 2003.
37. Balon J, Aker PD, Crowther ER, Danielson C, Cox PG, O'Shaughnessy D, et al. A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. N Eng J Med 1998;339:1013-20.
38. Asher MI, Douglas C, Airy M, Andrews D, Trenholme A. Effects of chest physical therapy on lung function in children recovering from acute severe asthma. Pediatr Pulmonol 1990;9:146-51.
39. Field T, Henteleff T, Hernandez-Reif M, Martinez E, Mavunda K, Kuhn C, et al. Children with asthma have improved pulmonary functions after massage therapy. J Pediatr 1998; 132:854-8.
40. Nielsen NH, Bronfort G, Bendix T, Madsen F, Weeke B. Chronic asthma and chiropractic spinal manipulation: a randomized clinical trial. Clin Exp Allergy 1995;25:80-8.
41. Kind P. The EuroQoL instrument: an index of health-related quality of life. In Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott-Raven; 1996. pp.191-201.
42. Greene WH. Econometric analysis, 4th edn. Englewood Cliffs, NJ: Prentice Hall; 2000.
43. Department of Health. 1996 Health Survey for England. London: DH; 1998.
44. Matthews JNS, Altman D, Campbell MJ. Analysis of serial measurements in medical research. BMJ 1990;300:230-5.
45. Petersen LN, Faurschou P, Olsen OT, Svendsen UG. Footzone therapy and bronchial asthma - a clinically controlled investigation. Ugeskr Laeger 1992;154:2065-8.
46. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQoL: results from a UK general population survey. Discussion Paper 138. York: University of York; Centre for Health Economics; 1995.
47. Green guide online. London: Green Guides; 2002.
48. Crick P. URL: filey-therapist.co.uk. Accessed August 2002.
49. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary 43rd ed. London: Pharmaceutical Press; 2002.
50. Netten A, Dennett J, Knight J. The unit costs of health and social care. Canterbury: Personal Social Services Research Unit; 2001.
51. Chartered Institute of Public Finance and Accountancy (CIPFA). Health service financial database 2001, London: CIPFA; 2001.
52. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. J Health Econ 1993;12:459-67.
53. Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ 1994;3:309-19.
54. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323(4):1300-3.
55. Office for National Statistics. The General Household Survey 2000-2001. London: ONS; 2001.
56. Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis (Cochrane Review). In The Cochrane Library (Issue 2). Oxford: Update Software; 2003.
57. May B, Munt P. Physiologic effects of chest percussion and postural drainage in patients with stable chronic bronchitis. Chest 1979;75:29-32.
58. Savci S, Ince D, Arikan H. A comparison of autogenic drainage and the active cycle of breathing techniques in patients with chronic obstructive pulmonary diseases. J Cardiopulm Rehabil 2000;20:37-43.
59. Bateman J, Newman S, Daunt K, Sheahan N, Pavia D, Clarke SW. Is cough as effective as chest physiotherapy in the removal of excessive tracheobronchial secretions? Thorax 1981;36:683-7.
60. Mohsenifar Z, Rosenberg N, Goldberg H, Koerner SK. Mechanical vibration and conventional chest physiotherapy in outpatients with stable chronic obstructive lung disease. Chest 1985;87:483-5.
61. Newton D, Bevans HG. Physiotherapy and intermittent positive-pressure ventilation of chronic bronchitis. BMJ 1978;ii:1525-8.
62. Olseni L, Midgren B, Hornblad Y, Wollmer R Chest physiotherapy in chronic obstructive pulmonary disease: forced expiratory technique combined with either postural drainage or positive expiratory pressure breathing. Respir Med 1994; 88:435-40.
63. Oldenburg F, Dolovich M, Montgomery J, Newhouse MT Effects of postural drainage, exercise and cough on mucous clearance in chronic bronchitis. Am Rev Respir Dis 1979; 120:739-45.
64. Sutton P, Parker R, Webber B, Newman S, Garland N, Lopez-Vidriero M, et al. Assessment of the forced expiration technique, postural drainage and directed coughing in chest physiotherapy. Eur J Res Dis 1983;64:62-8.
65. Scottish Parliament. Lung disease in Scotland. Edinburgh: The Scottish Parliament, June 2001.
66. Office for National Statistics. Census 2001 population in England and Wales. London: ONS; 2002.
67. Meads C, Salas CRT, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness and cost utility of photodynamic therapy for wet age-related macular degeneration. Birmingham: West Midlands Health Technology Assessment Group, University of Birmingham; January 2002.
68. Royal College of Ophthalmologists. Age related macular Degeneration: Guidelines. London: Royal College of Ophthalmologists; February 2000.
69. AMD Alliance International. Amsler grid: check your eyesight. Ontario: AMD Alliance International; 2002.
70. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409.
71. Smith D, Fenn P, Drummond M. Cost and effectiveness of photodynamic therapy with verteporfin for age-related macular degeneration: the UK case. Br J Ophthalmol, forthcoming.
72. Gregor Z, Bird AC, Chisholm IH. Senile disciform macular degeneration in the second eye. Br J Ophthalmol 1977;61:141-7.
73. Schuchard R. Validity and interpretation of Amsler grid reports. Arch Ophthalmol 1993; 111:776-80.
74. Fine AM, Elmen MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986;104:513-14.
75. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000; 20:325-30.
76. Bressler N. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001; 119:198-207.
77. Brown M, Brown G, Sharma S, Kistlet J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-31.
78. Williams GJ, Lee A, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children (Cochrane Review). In The Cochrane Library (Issue 4). Oxford: Update Software; 2003.
79. Winberg J, Bergstrom T, Jacobsson B. Morbidity, age and sex distribution, recurrences and renal scarring in symptomatic urinary tract infection in childhood. Kidney Int 1975;Suppl 4:S101-6.
80. Downs S. Technical Report: Urinary tract infections in febrile infants and young children. Pediatrics 1999;103:e54.
81. Smellie JM, Katz G, Gruneberg RN. Controlled trial of prophylactic treatment in childhood urinary tract infection. Lancet 1978;ii:175-8.
82. Savage DCL, Howie G, Adler K, Wilson MI. Controlled trial of therapy in covert bacteriuria of childhood. Lancet 1975;i:58-61.
83. Stansfeld JM. Duration of treatment for urinary tract infections in children. BMJ 1975;3:65-6.
84. Brendstrup L, Hjelt K, Petersen KE, Petersen S, Andersen EA, Daugbjerg PS, et al. Nitrofurantoin versus trimethoprim prophylaxis in recurrent urinary tract infection in children: a randomized, double-blind study. Acta Paediatr Scand 1990; 79:1225-34.
85. Jodal U. The natural history of bacteriuria in childhood. Infect Dis Clin North Am 1987; 1:713-29.
86. Alexander SR, Arbus GS, Butt KMH, Conley S, Fine RN, Greifer I, et al. The 1989 Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1990;4:542-553.
87. Arant BS, Jr. Vesicoureteric reflux and renal injury. Am J Kidney Dis. 1991;17:491-511.
88. Jacobson SH, Hansson S, Jakobsson B. Vesicoureteric reflux: occurrence and long-term risks. Acta Paediatr 1999;88(Suppl):22-30.
89. Mowatt G, Vale L, Perez P, Wyness L, Fraser C, MacLeod A, et al. Systematic review of the effectiveness and cost-effectiveness of home versus hospital or satellite unit haemodialysis for people with end stage renal failure. London: National Institute for Clinical Excellence; 2002.
90. Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women. J Fam Pract 1997;44:49-60.
91. Wahn F, Daniel V, Kronenberg F, Opelz G, Michalk DV, Querfeld U. Impact of apolipoprotein(a) phenotypes on long-term renal transplant survival. J Am Soc Nephrol 2001;12:1052-8.
92. Roberts SD, Gross TL, Maxwell DR. Examining alternative end-stage renal disease (ESRD) therapies through simulation. Proceedings of the Twelfth Annual Simulation Symposium, Florida; 1979.
93. Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987;10:14-20.
94. Prevost TC, Abrams KR, Jones DR. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer. Stat Med 2000;19:3359-76.
95. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester: Wiley; 2003.
96. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Research 2001;10:277-303.
97. Halpern MT, Luce BR, Brown RE, Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998;1:131-47.
98. Ramsey SD. Evaluating evidence from a decision analysis. J Am Board Fam Pract 1999;12: 395-402.
99. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8. In press.
100. Sculpher MJ. Evaluating the cost-effectiveness of interventions designed to increase the utilisation of evidence-based guidelines. Fam Pract 2000; 17:S26-3 1.